PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.
Patients with psoriasis, psoriatic arthritis, and axial spondylarthritis using ixekizumab have a low incidence rate of cerebro-cardiovascular events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback